



## 2024 KNOWLEDGE-BASED HOME-STUDY CE FOR PHARMACISTS AND PHARMACY TECHNICIANS

### Primary Prevention and Statin Treatment in Older Patients

#### Speaker:

**Joseph Saseen, PharmD, BCPS, BCACP**

Associate Dean for Clinical Affairs

Professor, Department of Clinical Pharmacy; Professor, Department of Family Medicine

Skaggs School of Pharmacy and Pharmaceutical Science

University of Colorado Anschutz Medical Campus, Aurora, CO

#### Learning Objectives

Upon completion of this CE activity, the participant will be able to do the following:

#### Learning Objectives (for pharmacists):

- **Explain** ACC/AHA guideline recommendations and NLA/AGS Scientific Statement for management of hypercholesterolemia in older primary prevention patients
- **Review** adverse effects/warnings/precautions associated with the use of medications for hypercholesterolemia
- **Describe** new and emerging medications for the treatment of hypercholesterolemia, including medications that lower Lp(a)
- **Identify** older primary prevention patients that are candidates for hypercholesterolemia therapy

#### Learning Objectives (for pharmacy technicians):

- **Review** ACC/AHA guideline recommendations and NLA/AGS Scientific Statement for management of hypercholesterolemia in older primary prevention patients
- **List** adverse effects/warnings/precautions associated with the use of medications for hypercholesterolemia
- **Recognize** new and emerging medications for the treatment of hypercholesterolemia, including medications that lower Lp(a)

#### **Accreditation Information:**

**ACPE UAN:** 0122-0000-24-064-H01-P/T

**CPE Credit Hours:** 1.0 hour (0.1 CEU) of live CE credit

**Release Date:** November 1, 2024

**Expiration Date:** November 1, 2025

**Sponsorship:** This program is conducted solely by Premier and has no commercial or non-commercial support or sponsorship.

**Disclosure:** Dr. Saseen reports that he is a member of the AMGEN Lipid Monitoring Board for the VESALIUS and OCEAN(a) long-term CV outcome trials. In keeping with Premier CE policies, the presentation has undergone mitigation procedures including peer review. The planners and moderators for this activity have no relevant financial relationships with ineligible companies to disclose.



**System Requirements to Access the Webcast:** [Click here](#) to view CE webcast system requirements for the learner to complete the online activity, including the internet browser(s) supported and minimum versions of each, and the minimum memory, storage, processor, and internet

### How to obtain CE credit

1. Log on to <https://ce.continuumofcare.premierinc.com>
2. Click on the icon that corresponds to this Home-Study CE activity
3. Register for that Home-Study CE activity
4. View and listen to the recorded activity in its entirety
5. Complete both the learning assessment questions and the activity evaluation.

**Note:** A passing grade of **70%** or better is required to receive CE credit. Three opportunities will be provided to successfully complete the post-test.

Once all steps above are completed, participation will be provided to CPE Monitor.



Premier, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This CE activity is provided as a free, value-added service to Premier Continuum of Care pharmacy staff.

### Speaker Bio:

**Joseph Saseen** is Associate Dean for Clinical Affairs and Professor of Clinical Pharmacy and a Professor of Family Medicine at the University of Colorado Anschutz Medical Campus.

He is a clinical pharmacist in primary care who focuses on cardiovascular risk reduction and population health. Dr. Saseen is a Past President of the National Lipid Association (NLA), a fellow of ACCP, ASHP, APhA, and the American Heart Association, and a Master of the NLA. He is a Board-Certified Pharmacotherapy Specialist, a Board-Certified Ambulatory Care Pharmacist, and is certified as a Clinical Lipid Specialist. He was an author of the 2018 AHA/ACC/Multisociety cholesterol management guideline, the 2022 NLA Statin Intolerance Scientific Statement, and the joint NLA/AGS Scientific Statement Treating Hypercholesterolemia in Older Primary Prevention Patients.